Frazier raises new $377m venture, equity fund
This article was originally published in Scrip
Frazier Healthcare raised $377m for its seventh healthcare fund to make venture capital investments in pre-commercial drug development companies and provide growth equity for revenue-generating health care businesses.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.